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Joubert syndrome ( JBTS) is an autosomal-recessive disorder characterized by a distinctive mid-hindbrain malformation, developmental
delay with hypotonia, ocular-motor apraxia, and breathing abnormalities. Although JBTS was first described more than 40 years ago in
French Canadian siblings, the causal mutations have not yet been identified in this family nor in most French Canadian individuals
subsequently described.We ascertained a cluster of 16 JBTS-affected individuals from 11 families living in the Lower St. Lawrence region.
SNP genotyping excluded the presence of a common homozygous mutation that would explain the clustering of these individuals.
Exome sequencing performed on 15 subjects showed that nine affected individuals from seven families (including the original JBTS
family) carried rare compound-heterozygous mutations in C5ORF42. Two missense variants (c.4006C>T [p.Arg1336Trp] and
c.4690G>A [p.Ala1564Thr]) and a splicing mutation (c.7400þ1G>A), which causes exon skipping, were found in multiple subjects
that were not known to be related, whereas three other truncating mutations (c.6407del [p.Pro2136Hisfs*31], c.4804C>T
[p.Arg1602*], and c.7477C>T [p.Arg2493*]) were identified in single individuals. None of the unaffected first-degree relatives were
compound heterozygous for these mutations. Moreover, none of the six putative mutations were detected among 477 French Canadian
controls. Our data suggest that mutations in C5ORF42 explain a large portion of French Canadian individuals with JBTS.Joubert syndrome (JBTS [MIM 213300]) is an autosomal-
recessive disorder characterized by the presence of hypo-
tonia, apnea or hyperpnea in infancy, oculomotor apraxia,
and variable developmental delay or intellectual impair-
ment (reviewed in Sattar et al.1). The diagnostic hallmark
of JBTS is the presence of a complex malformation of the
midbrain-hindbrain junction that comprises cerebellar
vermis hypoplasia or aplasia, deepened interpeduncular
fossa, and elongated superior cerebellar peduncles. This
malformation appears like a molar tooth on an axial brain
MRI (magnetic resonance imaging). In a subset of individ-
uals, JBTS also involves other organs and results in cystic
kidneys, retinopathy, or polydactyly. JBTS is a genetically
heterogeneous condition for which 15 genes have been
described to date.2–19 All of these genes appear to play a
role in the development and/or function of nonmotile
cilia. Although JBTS was first described in French Canadian
siblings more than 40 years ago by Marie Joubert and
colleagues, until now, the causal mutations have not yet
been identified in the original family nor in most French
Canadians subjects.20,21
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(Figure 1). In total, we identified 16 living affected individ-
uals (from 11 unrelated families) who have at least one
grandparent originating from that region. Informed con-
sent was obtained from all individuals or their legal guard-
ians. This project was approved by our institutional ethics
committee. We were initially able to collect blood-derived
DNA from 15 of these individuals, including an affected
individual (II-1 in family 394; individual BD in Joubert
et al.20) from the original JBTS family described by Marie
Joubert and colleagues in 1969. There was a striking cluster
of seven families from the east end of the region (Matapedia
region); one family is fromMont-Joli (population of 6,568),
three families are from Amqui (population of 6,261), and
three other families are from Sayabec (population of
1,877). Individual II-1 from family 394 did not undergo
brain-imaging studies, but an MRI scan performed on her
brother (II-2) showed the molar-tooth sign (MTS) (Fig-
ure 2B).21 All the other affected individuals showed the
MTS and variable expression of the classical JBTS features.
The cohort included three families with two affected
siblings, and the parents were not affected in any family
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Figure 1. Distribution of Individuals with JBTS
in the Lower St. Lawrence Region
Numbers refer to families (pedigrees in Figure 2).
Note the cluster of families along Route 132,
which follows the Matapedia River.It was initially established that the population of the
Lower St. Lawrence region was a result of both the immi-
gration of a limited number of settlers (6,000 individuals)
from Quebec City and its surrounding areas in the late
17th century and beginning of the 18th century and a rapid
increase in settlers resulting from a high fertility rate.22
The establishment of settlers in the region followed a
west-to-east pattern, and settlers later migrated to regions
farther east. A small number of Acadians also contributed
to the early population of the Matapedia region.23 The
demographic growth of this population thus appears to
be characterized by a series of bottlenecks that might
have resulted in regional founder effects. We hypothesized
that a founder effect could underlie the clustering of
individuals with JBTS in the Lower St. Lawrence region,
raising the possibility that a common homozygous muta-
tion explains a large portion of them. We performed
whole-genome SNP genotyping in all 15 individuals with
JBTS by using the Illumina Human 610 Genotyping
BeadChip panel, which interrogates 620,901 SNPs, and
we used PLINK24 to search for homozygosity regions con-
taining >30 consecutive SNPs and extending over >1Mb.
We identified several overlapping regions of shared
homozygosity, but these regions were not found in more
than five families, were small (1 megabase or less), and
contained genes that are unlikely to play a role in cilia
development and/or function (Table S1, available online).
Altogether, the genotyping data suggest the presence of
allelic and/or genetic heterogeneity within our cohort.
Given the lack of hints from genotype-based mapping,
we decided to sequence the protein-coding exomes of all
our JBTS-affected subjects in the hopes of identifying a
unique candidate gene harboring private pathogenic vari-
ants in a large fraction of the samples. Genomic DNA from
each sample was captured with the Agilent SureSelect694 The American Journal of Human Genetics 90, 693–700, April 6, 201250 Mb oligonucleotide library, and the
captured DNA was sequenced with paired-
end 100 bp reads on Illumina HiSeq2000.
The result was an average of 14.7 Gb of
raw sequence for each sample. Data were
analyzed as previously described.25 After
we used Picard (v. 1.48) to remove putative
PCR-generated duplicate reads, we aligned
the reads to human genome assembly
hg19 by using a Burroughs-Wheeler algo-
rithm (BWA v. 0.5.9). The median read
depth of the bases in CCDS (consensus
coding sequence) exons was 115 (deter-
mined with Broad Institute Genome
Analysis Toolkit v. 1.0.4418).26 On average,88% (52.9%) of the bases in CCDS exons were covered
by at least 20 reads. We called sequence variants by
using custom scripts for Samtools (v. 0.1.17), Pileup, and
varFilter, and we required at least three variant reads as
well as >20% variant reads for each called position.
Single-nucleotide variants (SNVs) had Phred-like quality
scores of at least 20, and small insertions or deletions
(indels) had scores of at least 50. We used Annovar to
annotate variants according to the type of mutation,
occurrence in dbSNP, SIFT score, and 1,000 Genomes allele
frequency.27 To identify potentially pathogenic variants,
we filtered out (1) synonymous variants or intronic vari-
ants other than those affecting the consensus splice sites,
(2) variants seen in more than one of 261 exomes from
individuals with rare, monogenic diseases unrelated to
JBTS (these individuals were sequenced at the McGill
University and Genome Quebec Innovation Centre), and
(3) variants with a frequency greater than 0.5% in the
1,000 Genomes Browser (Tables 1 and 2).
We first examined the exome datasets to look for rare
variants in the 15 genes already associated with JBTS (these
genes are INPP5E [MIM 613037], TMEM216 [MIM 613277],
AHI1 [MIM 608894], NPHP1 [MIM 607100], CEP290
[MIM 610142], TMEM67 [MIM 609884], RPGRIP1L
[MIM 610937], ARL13B [MIM 608922], CC2D2A [MIM
612013], CXORF5 [MIM 300170], KIF7 [MIM 611254],
TCTN1 [MIM 609863], TCTN2 [MIM 613885], TMEM237
[MIM 614424], and CEP41)2–19 as well as in the JBTS
candidate gene, TTC21B (MIM 612014).28 Two individuals
(II-1 from family 484 and II-2 from family 473, Figure S2)
that are not known to be related were each found to be
carrying two heterozygous missense variants (c.4667A>T
[p.Asp1556Val] and c.3376G>A [p.Glu1126Lys]) in
CC2D2A (RefSeq accession number NM_001080522.2).13,14
These amino acids are highly conserved, and both
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Figure 2. Segregation of C5ORF42Muta-
tions in Families Affected by JBTSmutations are predicted to be deleterious according to
SIFT (scores < 0.05)29 and Polyphen-2 (scores > 0.90)30
(Figure S1). The c.4667A>T (p.Asp1556Val) mutation has
already been reported in individuals with JBTS.31 Segrega-
tion studies have indicated that the affected individuals
but none of their unaffected first-degree relatives were
compound heterozygous for these mutations (Figure S2).
We conclude that these mutations are probably patho-
genic. Both individuals have a mild phenotype. They
have oculomotor apraxia and only mild motor delay
(they walked at 18 [II-1 from family 484] and 19 [II-2 from
family 473] months of age and do not have gait ataxia).
The individual who is of school age performs well in
a regular classroom. Four additional individuals were sin-
gly heterozygous for rare variants in the other knownThe American Journal of HumaJBTS-associated genes; such variants
are c.265C>T (p.Leu89Phe) in
TMEM216 (M_001173991.2),
c.3257A>G (p.Glu1086Gly) in
AHI1 (NM_001134831), c.1600G>A
(p.Glu534Lys) in CEP290 (NM_
025114.3), and c.3032T>C
(p.Met1011Thr) in TTC21B (NM_
024753.4). Because each of these
genes has previously been associated
with recessive JBTS, these heterozy-
gous variants are unlikely to fully
explain the disorder that these indi-
viduals have.
We next looked at the whole-exome
data for the other protein-coding
genes containing homozygous or
multiple heterozygous variants in the
13 affected individuals who did not
have mutations in CC2D2A (Tables 1
and 2). Strikingly, five subjects,
including a member of the initial
JBTS family, carried two different
heterozygous variants in an un-
studied anonymous gene, C5ORF42
(NM_023073.3). Mutations in six
other genes were found in affected
individuals among sets of three
families (Tables 1 and2). Because these
latter genes (MUC5B, PLEC, FAT3, FLG,
TTN, and LAMA5) are known to accu-
mulate mutations at a high rate, they
are unlikely to be linked to the disease
(Table S2). All five affected individuals
with changes in C5ORF42 carried the
same missense mutation, c.4006C>T
(p.Arg1336Trp) (NM_023073.3), aswell as one of three different mutations: one mutation
that affects a consensus donor splice site, c.7400þ1G>A
(NM_023073.3), and two truncating mutations, c.6407del
(p.Pro2136Hisfs*31) and c.4804C>T (p.Arg1602*) (NM_
023073.3) (Figures 2 and 3 and Table 3). Sanger sequencing
in the five affected individuals confirmed the presence of
these variants. Segregation studies indicated that the
affected individuals, but not their unaffected first-degree
relatives, were compound heterozygotes for these variants
(Figure 2 and Table 3). Subsequently, wewere able to collect
DNA from individual II-2 (individual M.D.19-20), the
affected brother of II-1 in the initial JBTS family (family
394), and we found that he was compound heterozygous
for the same C5ORF42mutations identified in his affected
sister (Figure 2B and Table 3). None of these four variantsn Genetics 90, 693–700, April 6, 2012 695
Table 2. Genes with Rare Homozygous or Multiple Heterozygous
Variants from the Combined Exome Sequences from 13 Individuals
with JBTS
Number of Families
with Mutations
in the Same Gene
Number
of Genes Gene Identity
1 family 528 C5ORF42,.
2 families 16 C5ORF42, ACAN, ADAMTS18,
C10orf68, FSIP2, LRP1B,
MUC12, MUC16, MUC4,
MYO16, PKD1L2, PKHD1L1,
RGPD4, SHROOM4,
TMEM231, ZNF717
3 families 7 C5ORF42, MUC5B, PLEC,
FAT3, FLG, TTN, LAMA5
4 families 1 C5ORF42
5 families 1 C5ORF42
>5 families 0 -
Table 1. Variant Prioritization Steps in the Analysis of Combined
Exome Sequences from 13 Individuals with JBTS
Filters Applied (Sequentially)
Number of
Variants Retained
Nonsynonymous, splicing, and coding indel
variants
34,157a
After excluding variants present in >1
in-house exome
7,075
After excluding variants reported in 1,000
Genomes Browser (frequency > 0.5%)
6,911
aTotal number of variants identified in the combined 13 exomes; redundant
variants were counted only once.was detected in 261 in-house control exomes, which were
derived from other projects including some French Cana-
dian subjects, and in the 1,000 Genomes Browser. RT-PCR
performed on RNA extracted from the blood of individuals
II-2 (from family 394) and III-4 (from family 406/301), who
both carry the c.7400þ1G>A splicing mutation, showed
that this mutation causes skipping of exon 35 in C5ORF42
(NM_023073.3) and results in the creation of a premature
stop codon (Figure S3). The p.Arg1336Trp amino acid
substitution is predicted to be damaging (SIFT¼ 0.00; Poly-
phen-2 ¼ 0.99) and to affect a residue that is conserved
across vertebrate species (Figure 3B).
On the basis of the exome-sequencing data, four
additional JBTS-affected individuals from three families
(301, 468, and 489) were each carrying a single heterozy-
gous C5ORF42 mutation, including the already described
c.4006C>T (p.Arg1336Trp) and c.7400þ1G>A mutations
and the truncating mutation c.7477C>T (p.Arg2493*)
(NM_023073.3) (Figure 2 and Table 3). The c.7477C>T
(p.Arg2493*) mutation was absent from our 261 control
exomes and the 1,000 Genomes Browser. Our SNP geno-
typing data suggest that these four individuals—but not
the other individuals with JBTS in our cohort—are hetero-
zygous for a unique 5 Mb haplotype that encompasses
C5ORF42 (Figure S4). It seemed unlikely that this haplo-
type would be carrying three different rare mutations;
therefore, this observation suggests that the four individ-
uals might carry a second mutation linked to this haplo-
type. Upon further inspection of the exome data, we
discovered that all four individuals are also heterozygous
for another missense variant, c.4690G>A (p.Ala1564Thr)
(based on the ENST00000388739 transcript annotated by
the Ensemble Genome Browser). This allele was not
included in our original filtered dataset because it is located
in an internal coding exon (chr5: 37,157,522–37,157,415)
not annotated by RefSeq for the longest isoform of the
gene (NM_023073.3). Sanger sequencing confirmed the
presence of the various mutations in the four affected
individuals. Segregation studies showed that the four
affected individuals but none of their unaffected first-
degree relatives were compound heterozygous for
c.4690G>A (p.Ala1564Thr) and for one of the three other
mutations (c.4006C>T [p.Arg1336Trp], c.7400þ1G>A,696 The American Journal of Human Genetics 90, 693–700, April 6, 2and c.7477C>T [p.Arg2493*]) (Figure 2). The additional,
alternative exon (which we designate exon 40a) with the
c.4690G>A (p.Ala1564Thr) mutation occurs between
RefSeq annotated exons 40 and 41 (NM_023073.3), is
present in brain expressed sequence tag (EST) clones with
GenBank accession numbers AK096581 and BC144070,
and retains the large open reading frame of the gene. Using
RNA-sequencing data made publicly available by Illumi-
na’s Body Map 2.0 (see Web Resources), we were able to
confirm the expression of the exon. The assembly of raw
data from 16 different tissues identified a large number of
reads that mapped to that exon in both brain and testes
samples; significantly fewer reads mapped to other tissues
(Figure S5). Reads that covered both ends of the exon and
spliced correctly to neighboring exons were found in either
brain or testes samples. The c.4690G>A (p.Ala1564Thr)
mutation was also absent from our 261 control exomes
and from the 1,000 Genomes Browser. It was not possible
to get accurate SIFT or Polyphen-2 predictions for this
mutation because the corresponding exon was not anno-
tated across species.
We further addressed the frequency of the six putative
C5ORF42 mutations identified in our JBTS individuals in
the French Canadian population. Genotyping 477 French
Canadian controls, including 96 Acadians subjects and 96
subjects from the Gaspe´sie region located immediately east
of Matapedia, did not identify a carrier of any of the six
C5ORF42 mutations. However, some of these mutations
are reported in the heterozygous state at very low frequen-
cies in the National Heart, Lung, and Blood Institute
(NHLBI) Go Exome Sequencing Project (ESP) dataset; these
mutations are c.4006C>T (p.Arg1336Trp) (2/10,754;
minor allele frequency [MAF] ¼ 0.0186%), c.7477C>T
(p.Arg2493*) (1/10,755; MAF ¼ 0.009%; rs139675596),
and c.4690G>A (p.Ala1564Thr) (12/4,574; MAF ¼
0.262%; rs111294855). It should be noted that
c.4006C>T and c.7477C>T correspond to CpG sites,012
Figure 3. C5ORF42 Mutations Identified in Individuals with JBTS
(A) Scheme showing the positions of the mutations with respect to the different C5ORF42 Ensembl-annotated transcripts that are pre-
dicted to produce proteins. The numbering on top is based on the cDNA positions of ENST00000425232 (identical to RefSeq accession
number NM_023073.3). Mutation c.7957þ288G>A is annotated as part of a coding exon in ENST00000388739 and causes a missense
change (p.Ala1564Thr).
(B) NCBI HomoloGene-generated amino acid alignment of C5ORF42. Its predicted orthologs show the conservation of the Arg1336
residue.which are associated with a higher mutation rate, possibly
explaining the recurrence of these nonetheless rare muta-
tions in different populations.
The presence of five potentially deleterious C5ORF42
mutations that segregate with the disease in seven presum-
ably unrelated (though all French Canadian) families
strongly suggests that disruption of this gene causes JBTS
in our subjects. It remains uncertain whether c.4690G>A
(p.Ala1564Thr) is pathogenic, considering that it is not
clearly deleterious and that it is found at a higher
frequency (0.26%) in the ESP dataset than are the other
mutations. It is possible that this variant is linked to
another mutation—not identified by our exome-
sequencing approach—on the same haplotype.
Very little is known about C5ORF42 function. The Ref-
Seq version of the full-length transcript (NM_023073.3;
Ensemble accession number ENST00000425232) appar-
ently derives from virtual assembly of overlapping mRNA
and EST clones. The predicted major mRNA isoform
comprises 11,199 bp and contains 52 exons; the putative
encoded protein is similarly large and comprises 3,198The Amamino acids. With the exception of c.4690G>A
(p.Ala1564Thr), all mutations reported herein are common
to all annotated protein-coding transcripts (Figure 3A). The
predicted protein sequence is well conserved across much
of the gene length in other vertebrates. It does not appear
to contain any specific known functional domains,
although the Gene Ontology project suggests that it might
be a transmembrane protein and ProtoNet predicts a
coiled-coil structure within the protein. Proteomic studies
have reported interactions among C5ORF42, the p21-
activating kinase 1 (PAK1), and the small ubiquitin-like
modifier 1 (SUMO1).32,33 Although the significance of
these interactions remains to be validated and further
investigated, it is noteworthy that these latter genes play
a role in neural development.34,35 EST-expression (Unig-
ene data), microarray profiling (Allen Brain Atlas), and
BioGPS indicate that C5ORF42 is widely expressed in
a variety of tissues, including the brain.
In terms of genotype-phenotype correlation, all JBTS
individuals with mutations in C5ORF42 showed global
developmental delay, and the onset of independenterican Journal of Human Genetics 90, 693–700, April 6, 2012 697
Table 3. Clinical Description of JBTS Individuals with C5ORF42 Mutations
Genotype
Family 406/301 Family 394 Family 474 Family 480 Family 489 Family 479 Family 468
IV-1 IV-2 IV-3 II-1 II-2 II-1 II-1 II-1 II-1 II-1
c.4006C>T (p.Arg1336Trp) þ   þ þ þ þ  þ þ
c.7400þ1G>A þ þ þ þ þ  þ   
c.6407del (p.Pro2136Hisfs*31)      þ    
c.7477C>T (p.Arg2493*)        þ  
c.4804C>T (p.Arg1602*)         þ 
c.7957þ288G>A
(c.4690G>A [p.Ala1564Thr])
 þ þ     þ  þ
Age (years) 8 1.5 3 52 45 4 10 7 13 31
Sex F M F F M F M M F F
Developmental delay þ þ þ þ þ þ þ þ þ þ
Oculomotor apraxia  þ þ þ þ þ þ þ þ þ
Breathing abnormality þ þ þ þ þ þ þ þ  
Limb abnormalitya  þ    þ    
Brain MRI MTS MTS MTS ND MTS MTS MTS MTS MTS MTS
Retinal involvementb  (f)  (e)  (e)  (h)  (h)  (f)  (e)  (e)  (f)  (h)
Renal involvementc  (us)  (us)  (us)  (h)  (h)  (us)  (us)  (us)  (us)  (h)
The nucleotide and amino acid positions are based on reference sequence NM_023073.3 except for c.4690G>A (p.Ala1564Thr), which is based on Ensembl tran-
script ENST00000509849. The following abbreviations are used: F, female; M, male; MRI, magnetic resonance imaging; MTS, molar tooth sign; ND, not done; f,
fundoscopy; e, electroretinogram; h, history; and us, ultrasound.
aIndividual IV-2 from family 406/301 has a 3/4 syndactyly in the left hand and individual II.1 from family 474 has preaxial and postaxial polydactyly of the four
limbs. Individual II-1 from family 394 did not undergo an MRI, but the MRI of her brother (individual II-2 from family 394) documented a MTS.
bLack of retinal involvement was determined by electroretinogram, fundoscopy, or history.
cLack of renal involvement was determined by renal ultrasound or history.walking ranged between 30 months and 8 years of age
(Table 3). Cognitive impairment was present in all individ-
uals but was variable, ranging from borderline intelligence
to mild intellectual disability. The majority of individuals
also showed oculomotor apraxia and breathing abnormal-
ities mainly characterized by episodes of hyperventilation.
Two individuals showed limb abnormalities; one had
preaxial and postaxial polydactyly, and another had
syndactyly of the third and fourth finger on one hand.
There was no evidence of retinal or kidney involvement.
There was no clear correlation between the type of
C5ORF42 mutation and the associated phenotype.
Surprisingly, we found that three mutations (c.4006C>T
[p.Arg1336Trp], c.7400þ1G>A, and c.4690G>A
[p.Ala1564Thr]) in C5ORF42 were present in multiple
individuals in our cohort. Haplotype studies indicate that
each of these mutations is linked to a distinct haplotype
in these families despite the lack of documented genealog-
ical relationships among them (Figure S4). The higher
frequency of these mutations in the population of the
Lower St. Lawrence region could be explained by a founder
effect with the coincidental occurrence of the three muta-
tions in the same group of settlers or by multiple regional
founder effects corresponding to sequential pioneer fronts.
Although founder effects are typically associated with an
increase in the frequency of a specific allele,33 which is698 The American Journal of Human Genetics 90, 693–700, April 6, 2often accompanied by other alleles that remain at their
usual background frequency, they can also involve
multiple common mutations.36,37
In summary, after the initial description of JBTS in a
French Canadian family 40 years ago, we have shown
that mutations in C5ORF42 explain this neurodevelop-
mental disorder in many affected individuals from the
French Canadian population. We have also found that
C5ORF42 is associated with a complex founder effect in
this population. Although the function of C5ORF42
remains unknown, future studies will likely elucidate its
role in cilia development and/or function.Supplemental Data
Supplemental Data include five figures and two tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
Foremost, we thank the families who generously contributed their
time and materials to this research study. This work was selected
for study by the FORGE Canada Steering Committee, consisting
of K. Boycott (University of Ottawa), J. Friedman (University of
British Columbia), J. Michaud (Universite´ de Montre´al), F. Bernier
(University of Calgary), M. Brudno (University Toronto), B. Fer-
nandez (Memorial University), B. Knoppers (McGill University),012
M. Samuels (Universite´ de Montre´al), and S. Scherer (University of
Toronto). We would like to thank Janet Marcadier (clinical
coordinator) and Chandree Beaulieu (project manager) for their
contribution to the infrastructure of the FORGE Canada Consor-
tium. The authors also wish to acknowledge the contribution of
the high-throughput sequencing platform of the McGill
University and Genome Que´bec Innovation Centre (Montre´al,
Canada). This work was funded by the Government of Canada
through Genome Canada, the Canadian Institutes of Health
Research (CIHR), and the Ontario Genomics Institute (OGI-049).
Additional funding was provided by Genome Que´bec and
Genome British Columbia. K. Boycott is supported by a Clinical
Investigatorship Award from the CIHR Institute of Genetics.
J.L. Michaud is a National Scholar from the Fonds de la Recherche
en Sante´ du Que´bec (FRSQ). M. Srour holds a training award from
the FRSQ.
Received: December 15, 2011
Revised: January 23, 2012
Accepted: February 13, 2012
Published online: March 15, 2012Web Resources
The URLs for data presented herein are as follows:
1,000 Genomes Browser, http://browser.1000genomes.org/index.
html
Allen Brain Atlas, http://www.brain-map.org/
BioGPS, http://biogps.org
dbSNP, http://www.ncbi.nlm.nih.gov/projects/SNP/
Ensemble Genome Browser, http://www.ensembl.org
ESP Exome Variant Server, http://evs.gs.washington.edu/EVS/
Gene Ontology, http://www.geneontology.org/
Illumina’s Body Map 2.0 transcriptome, http://www.ebi.ac.uk/
arrayexpress/browse.html?keywords ¼ E-MTAB-513
NCBI HomoloGene, http://www.ncbi.nlm.nih.gov/homologene
NCBI Nucleotide Database, http://www.ncbi.nlm.nih.gov/nuccore
Online Mendelian Inheritance in Man (OMIM), http://www.
omim.org
Polyphen-2, http://genetics.bwh.harvard.edu/pph2/
SIFT, http://sift.jcvi.org/
Unigene, http://www.ncbi.nlm.nih.gov/unigeneReferences
1. Sattar, S., and Gleeson, J.G. (2011). The ciliopathies in
neuronal development: a clinical approach to investigation
of Joubert syndrome and Joubert syndrome-related disorders.
Dev. Med. Child Neurol. 53, 793–798.
2. Bielas, S.L., Silhavy, J.L., Brancati, F., Kisseleva, M.V., Al-Gazali,
L., Sztriha, L., Bayoumi, R.A., Zaki, M.S., Abdel-Aleem, A.,
Rosti, R.O., et al. (2009). Mutations in INPP5E, encoding
inositol polyphosphate-5-phosphatase E, link phosphatidyl
inositol signaling to the ciliopathies. Nat. Genet. 41, 1032–
1036.
3. Edvardson, S., Shaag, A., Zenvirt, S., Erlich, Y., Hannon, G.J.,
Shanske, A.L., Gomori, J.M., Ekstein, J., and Elpeleg, O.
(2010). Joubert syndrome 2 (JBTS2) in Ashkenazi Jews is
associated with a TMEM216 mutation. Am. J. Hum. Genet.
86, 93–97.The Am4. Valente, E.M., Logan, C.V., Mougou-Zerelli, S., Lee, J.H.,
Silhavy, J.L., Brancati, F., Iannicelli, M., Travaglini, L., Romani,
S., Illi, B., et al. (2010). Mutations in TMEM216 perturb cilio-
genesis and cause Joubert, Meckel and related syndromes.
Nat. Genet. 42, 619–625.
5. Dixon-Salazar, T., Silhavy, J.L., Marsh, S.E., Louie, C.M., Scott,
L.C., Gururaj, A., Al-Gazali, L., Al-Tawari, A.A., Kayserili, H.,
Sztriha, L., and Gleeson, J.G. (2004). Mutations in the AHI1
gene, encoding jouberin, cause Joubert syndrome with
cortical polymicrogyria. Am. J. Hum. Genet. 75, 979–987.
6. Parisi, M.A., Bennett, C.L., Eckert, M.L., Dobyns, W.B., Glee-
son, J.G., Shaw, D.W., McDonald, R., Eddy, A., Chance, P.F.,
and Glass, I.A. (2004). The NPHP1 gene deletion associated
with juvenile nephronophthisis is present in a subset of indi-
viduals with Joubert syndrome. Am. J. Hum. Genet. 75, 82–91.
7. Valente, E.M., Silhavy, J.L., Brancati, F., Barrano, G., Krishnas-
wami, S.R., Castori, M., Lancaster, M.A., Boltshauser, E., Boc-
cone, L., Al-Gazali, L., et al; International Joubert Syndrome
Related Disorders Study Group. (2006). Mutations in
CEP290, which encodes a centrosomal protein, cause pleio-
tropic forms of Joubert syndrome. Nat. Genet. 38, 623–625.
8. Sayer, J.A., Otto, E.A., O’Toole, J.F., Nurnberg, G., Kennedy,
M.A., Becker, C., Hennies, H.C., Helou, J., Attanasio, M.,
Fausett, B.V., et al. (2006). The centrosomal protein nephro-
cystin-6 is mutated in Joubert syndrome and activates
transcription factor ATF4. Nat. Genet. 38, 674–681.
9. Baala, L., Romano, S., Khaddour, R., Saunier, S., Smith,U.M., Au-
dollent, S., Ozilou, C., Faivre, L., Laurent, N., Foliguet, B., et al.
(2007). The Meckel-Gruber syndrome gene, MKS3, is mutated
in Joubert syndrome. Am. J. Hum. Genet. 80, 186–194.
10. Arts, H.H., Doherty, D., van Beersum, S.E., Parisi, M.A.,
Letteboer, S.J., Gorden, N.T., Peters, T.A., Ma¨rker, T., Voesenek,
K., Kartono, A., et al. (2007). Mutations in the gene encoding
the basal body protein RPGRIP1L, a nephrocystin-4 interactor,
cause Joubert syndrome. Nat. Genet. 39, 882–888.
11. Delous, M., Baala, L., Salomon, R., Laclef, C., Vierkotten, J.,
Tory, K., Golzio, C., Lacoste, T., Besse, L., Ozilou, C., et al.
(2007). The ciliary gene RPGRIP1L is mutated in cerebello-
oculo-renal syndrome (Joubert syndrome type B) and Meckel
syndrome. Nat. Genet. 39, 875–881.
12. Cantagrel, V., Silhavy, J.L., Bielas, S.L., Swistun, D., Marsh,
S.E., Bertrand, J.Y., Audollent, S., Attie´-Bitach, T., Holden,
K.R., Dobyns, W.B., et al; International Joubert Syndrome
Related Disorders Study Group. (2008). Mutations in the cilia
gene ARL13B lead to the classical form of Joubert syndrome.
Am. J. Hum. Genet. 83, 170–179.
13. Noor, A.,Windpassinger, C., Patel, M., Stachowiak, B., Mikhai-
lov, A., Azam, M., Irfan, M., Siddiqui, Z.K., Naeem, F., Pater-
son, A.D., et al. (2008). CC2D2A, encoding a coiled-coil and
C2 domain protein, causes autosomal-recessive mental retar-
dation with retinitis pigmentosa. Am. J. Hum. Genet. 82,
1011–1018.
14. Gorden, N.T., Arts, H.H., Parisi, M.A., Coene, K.L., Letteboer,
S.J., van Beersum, S.E., Mans, D.A., Hikida, A., Eckert, M.,
Knutzen, D., et al. (2008). CC2D2A is mutated in Joubert
syndrome and interacts with the ciliopathy-associated basal
body protein CEP290. Am. J. Hum. Genet. 83, 559–571.
15. Dafinger, C., Liebau, M.C., Elsayed, S.M., Hellenbroich, Y.,
Boltshauser, E., Korenke, G.C., Fabretti, F., Janecke, A.R., Eber-
mann, I., Nu¨rnberg, G., et al. (2011). Mutations in KIF7 link
Joubert syndrome with Sonic Hedgehog signaling and micro-
tubule dynamics. J. Clin. Invest. 121, 2662–2667.erican Journal of Human Genetics 90, 693–700, April 6, 2012 699
16. Garcia-Gonzalo, F.R., Corbit, K.C., Sirerol-Piquer, M.S., Ramas-
wami, G., Otto, E.A., Noriega, T.R., Seol, A.D., Robinson, J.F.,
Bennett, C.L., Josifova, D.J., et al. (2011). A transition zone
complex regulates mammalian ciliogenesis and ciliary
membrane composition. Nat. Genet. 43, 776–784.
17. Sang, L., Miller, J.J., Corbit, K.C., Giles, R.H., Brauer, M.J.,
Otto, E.A., Baye, L.M., Wen, X., Scales, S.J., Kwong, M., et al.
(2011). Mapping the NPHP-JBTS-MKS protein network
reveals ciliopathy disease genes and pathways. Cell 145,
513–528.
18. Huang, L.J., Szymanska, K., Jensen, V.L., Janecke, A.R., Innes,
A.M., Davis, E.E., Frosk, P., Li, C.M., Willer, J.R., Chodirker,
B.N., et al. (2011). TMEM237 is mutated in individuals with
a Joubert syndrome related disorder and expands the role of
the TMEM family at the ciliary transition zone. Am. J. Hum.
Genet. 89, 713–730.
19. Lee, J.E., Silhavy, J.L., Zaki, M.S., Schroth, J., Bielas, S.L.,
Marsh, S.E., Olvera, J., Brancati, F., Iannicelli, M., Ikegami,
K., et al. (2012). CEP41 is mutated in Joubert syndrome and
is required for tubulin glutamylation at the cilium. Nat.
Genet. 44, 193–199.
20. Joubert, M., Eisenring, J.J., Robb, J.P., and Andermann, F.
(1969). Familial agenesis of the cerebellar vermis. A syndrome
of episodic hyperpnea, abnormal eye movements, ataxia, and
retardation. Neurology 19, 813–825.
21. Andermann, F., Andermann, E., Ptito, A., Fontaine, S., and
Joubert, M. (1999). History of Joubert syndrome and a 30-
year follow-up of the original proband. J. Child Neurol. 14,
565–569.
22. Fortin, J.C., and Lechasseur, A. (1999). Le Bas-Saint-Laurent
(Que´bec: Presses de l’Universite´ Laval).
23. He´bert, P.M. (1994). Les Acadiens du Que´bec (Montre´al:
E´ditions de l0e´cho).
24. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira,
M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly,
M.J., and Sham, P.C. (2007). PLINK: A tool set for whole-
genome association and population-based linkage analyses.
Am. J. Hum. Genet. 81, 559–575.
25. Majewski, J., Schwartzentruber, J.A., Caqueret, A., Patry, L.,
Marcadier, J., Fryns, J.P., Boycott, K.M., Ste-Marie, L.G.,
McKiernan, F.E., Marik, I., et al; FORGE Canada Consortium.
(2011). Mutations in NOTCH2 in families with Hajdu-Cheney
syndrome. Hum. Mutat. 32, 1114–1117.
26. McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis,
K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly,
M., and DePristo, M.A. (2010). The Genome Analysis Toolkit:700 The American Journal of Human Genetics 90, 693–700, April 6, 2A MapReduce framework for analyzing next-generation DNA
sequencing data. Genome Res. 20, 1297–1303.
27. Wang, K., Li, M., and Hakonarson, H. (2010). ANNOVAR:
Functional annotation of genetic variants from high-
throughput sequencing data. Nucleic Acids Res. 38, e164.
28. Davis, E.E., Zhang, Q., Liu, Q., Diplas, B.H., Davey, L.M., Hart-
ley, J., Stoetzel, C., Szymanska, K., Ramaswami, G., Logan,
C.V., et al; NISC Comparative Sequencing Program. (2011).
TTC21B contributes both causal and modifying alleles across
the ciliopathy spectrum. Nat. Genet. 43, 189–196.
29. Kumar, P., Henikoff, S., and Ng, P.C. (2009). Predicting the
effects of coding non-synonymous variants on protein func-
tion using the SIFT algorithm. Nat. Protoc. 4, 1073–1081.
30. Adzhubei, I.A., Schmidt, S., Peshkin, L., Ramensky, V.E., Gera-
simova, A., Bork, P., Kondrashov, A.S., and Sunyaev, S.R.
(2010). A method and server for predicting damaging
missense mutations. Nat. Methods 7, 248–249.
31. Mougou-Zerelli, S., Thomas, S., Szenker, E., Audollent, S.,
Elkhartoufi, N., Babarit, C., Romano, S., Salomon, R., Amiel,
J., Esculpavit, C., et al. (2009). CC2D2A mutations in Meckel
and Joubert syndromes indicate a genotype-phenotype corre-
lation. Hum. Mutat. 30, 1574–1582.
32. Bandyopadhyay, S., Chiang, C.Y., Srivastava, J., Gersten, M.,
White, S., Bell, R., Kurschner, C., Martin, C.H., Smoot, M.,
Sahasrabudhe, S., et al. (2010). A human MAP kinase interac-
tome. Nat. Methods 7, 801–805.
33. Ganesan, A.K., Kho, Y., Kim, S.C., Chen, Y., Zhao, Y., and
White, M.A. (2007). Broad spectrum identification of SUMO
substrates in melanoma cells. Proteomics 7, 2216–2221.
34. Huang, W., Zhou, Z., Asrar, S., Henkelman, M., Xie, W., and
Jia, Z. (2011). p21-Activated kinases 1 and 3 control brain
size through coordinating neuronal complexity and synaptic
properties. Mol. Cell. Biol. 31, 388–403.
35. Wilkinson, K.A., Nakamura, Y., and Henley, J.M. (2010).
Targets and consequences of protein SUMOylation in
neurons. Brain Res. Brain Res. Rev. 64, 195–212.
36. Yotova, V., Labuda, D., Zietkiewicz, E., Gehl, D., Lovell, A.,
Lefebvre, J.F., Bourgeois, S., Lemieux-Blanchard, E., Labuda,
M., Ve´zina, H., et al. (2005). Anatomy of a founder effect:
Myotonic dystrophy in Northeastern Quebec. Hum. Genet.
117, 177–187.
37. Roddier, K., Thomas, T., Marleau, G., Gagnon, A.M., Dicaire,
M.J., St-Denis, A., Gosselin, I., Sarrazin, A.M., Larbrisseau, A.,
Lambert, M., et al. (2005). Two mutations in the HSN2 gene
explain the high prevalence of HSAN2 in French Canadians.
Neurology 64, 1762–1767.012
